Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy-free BTK inhibitor + PD-1 + XPO1 regimen in relapsed/refractory DLBCL
ChiCTR2200060630Phase 2Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Sichuan Provincial People's Hospital. Primary endpoint: overall response rate at 2 months. Planned start May 2022; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2200060630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060630.